Get all your news in one place.
100's of premium titles.
One app.
Start reading
Benzinga
Benzinga
Technology
Ragothaman Srinivasan

RARE PHOTOS: Jasper therapeutics presented updated data from phase 1 clinical trial of jsp191 - The Real Truth

Jasper Therapeutics, Inc., (NASDAQ:JSPR) announced updated efficacy, safety and pharmacokinetic data from its Phase 1 clinical trial of JSP191, in older patients with myelodysplastic syndromes (MDS) or acute myeloid leukemia (AML) undergoing allogeneic hematopoietic (blood) cell transplantation.

The data readout revealed, in Phase 1b dose expansion study, with 24 patients suffering from myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML), JSP191 is well tolerated with no treatment-related severe adverse events.

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.